Atlas Trials

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Clinical trial NCT03061539 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03061539
Sponsor
University College, London
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Prostate Cancer
Start date
2018-02-06
Primary completion
2022-06-20
Enrollment
380

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.